Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update

• Published in: Pharmaceutics Vol. 13; no. 10; p. 1568
• Main Authors: Mishra, Vijay, Nayak, Pallavi, Sharma, Mayank, Albutti, Aqel, Alwashmi, Ameen S S, Aljasir, Mohammad Abdullah, Alsowayeh, Noorah, Tambuwala, Murtaza M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.09.2021; MDPI
• Subjects: Adenosine; blood glucose level; Chronic illnesses; Diabetes; diabetes mellitus; Drug delivery systems; Drug dosages; Enzymes; Glucagon; Glucose; insulin; Insulin resistance; Kinases; Metabolism; nanocarrier; Peptides; Review; treatment strategies; China; India; blood glucose level; nanocarrier; treatment strategies; diabetes mellitus; insulin
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics13101568

The occurrence of diabetes mellitus (DM) is increasing rapidly at an accelerating rate worldwide. The status of diabetes has changed over the last three generations; whereas before it was deemed a minor disease of older people but currently it is now one of the leading causes of morbidity and mortality among middle-aged and young people. High blood glucose-mediated functional loss, insulin sensitivity, and insulin deficiency lead to chronic disorders such as Type 1 and Type 2 DM. Traditional treatments of DM, such as insulin sensitization and insulin secretion cause undesirable side effects, leading to patient incompliance and lack of treatment. Nanotechnology in diabetes studies has encouraged the development of new modalities for measuring glucose and supplying insulin that hold the potential to improve the quality of life of diabetics. Other therapies, such as β-cells regeneration and gene therapy, in addition to insulin and oral hypoglycemic drugs, are currently used to control diabetes. The present review highlights the nanocarrier-based drug delivery systems and emerging treatment strategies of DM.